View Future GrowthTrivarX 과거 순이익 실적과거 기준 점검 0/6TrivarX은 연평균 19.6%의 비율로 수입이 증가해 온 반면, Healthcare Services 산업은 연평균 22.9%의 비율로 증가했습니다. 매출은 연평균 9.2%의 비율로 감소했습니다.핵심 정보19.59%순이익 성장률36.99%주당순이익(EPS) 성장률Healthcare Services 산업 성장률1.72%매출 성장률-9.22%자기자본이익률-8.96%순이익률2,213.15%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing공시 • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing공시 • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing공시 • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia공시 • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing공시 • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing공시 • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia공시 • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.공시 • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listing공시 • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia공시 • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.매출 및 비용 세부 내역TrivarX가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:MDBI.F 매출, 비용 및 순이익 (AUD Millions)날짜매출순이익일반관리비연구개발비31 Dec 250-21030 Sep 250-21030 Jun 251-11031 Mar 252-11031 Dec 24201030 Sep 241-11030 Jun 241-11031 Mar 240-31031 Dec 230-41030 Sep 230-31030 Jun 231-31031 Mar 231-81131 Dec 221-121130 Sep 221-131130 Jun 221-131131 Mar 221-71131 Dec 211-11030 Sep 211-11030 Jun 211-11031 Mar 211-21031 Dec 201-21030 Sep 201-31030 Jun 201-42031 Mar 201-42031 Dec 191-52130 Sep 193-63130 Jun 194-75031 Mar 193-116131 Dec 183-158230 Sep 183-157330 Jun 182-167331 Mar 183-155531 Dec 173-134630 Sep 173-113530 Jun 173-102431 Mar 173-92331 Dec 164-71230 Sep 163-71230 Jun 162-61231 Mar 162-61131 Dec 151-70030 Sep 151-70030 Jun 150-800양질의 수익: MDBI.F 은(는) 현재 수익성이 없습니다.이익 마진 증가: MDBI.F는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: MDBI.F는 수익성이 없지만 지난 5년 동안 연평균 19.6%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 MDBI.F의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: MDBI.F은 수익성이 없어 지난 해 수익 성장률을 Healthcare Services 업계(4.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: MDBI.F는 현재 수익성이 없으므로 자본 수익률이 음수(-8.96%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/14 17:22종가2026/05/06 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스TrivarX Limited는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Stuart RobertsPitt Street Research Pty Ltd.
공시 • Dec 19TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.2 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 437,725,337 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
공시 • Oct 27TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
공시 • Oct 16TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 0.698197 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 87,274,663 Price\Range: AUD 0.008 Discount Per Security: AUD 0.00048 Transaction Features: Subsequent Direct Listing
공시 • Sep 26TrivarX Limited, Annual General Meeting, Nov 21, 2025TrivarX Limited, Annual General Meeting, Nov 21, 2025. Location: at the companys registered office, at 647 beaufort street, mount lawley, Australia
공시 • May 20TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has completed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
공시 • Mar 17TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.25 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 102,818,898 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 47,181,102 Price\Range: AUD 0.015 Discount Per Security: AUD 0.0009 Transaction Features: Subsequent Direct Listing
공시 • Oct 09TrivarX Limited, Annual General Meeting, Nov 28, 2024TrivarX Limited, Annual General Meeting, Nov 28, 2024. Location: 647 beaufort street, mount lawley, western australia., western australia. Australia
공시 • Sep 25TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024TrivarX Limited announced that it has strengthened the composition of its Board with the appointment of Mr. John H. Mathias II as a Non-executive Director, effective 1 October 2024. Mr. Mathias is an accomplished healthcare focused operations and business development executive, with a clinical background in respiratory care. He has a demonstrated track record of success over a 30-year career in the US healthcare industry. Currently, he holds the role of Chief Development Officer at Medbridge Healthcare. MedBridge also has a number of professional partnerships that support adjacent services including hospital readmission reduction programs (HRRP), product and drug research, occupational health, professional services and therapeutic sleep offerings. As CDO, he plays a central role in building partnerships with stakeholders across the US healthcare system in the field of sleep medicine including hospitals, medical research institutions, clinical partnerships, and insurance companies. Prior to his role as CDO, Mr. Mathias also served as Chief Operating Officer and President of Sleep Services of America Inc., an entity of Johns Hopkins Health System, where he managed operations for sleep diagnostics and therapeutic coordination, oversaw strategic M&A and led a business turnaround which returned the division to profitability. Throughout his career, Mr. Mathias has been recognised for building and leading high-performing healthcare managers and sales teams and implementing strategic business plans to drive consistent growth in revenue and margin levels. With direct experience across several US healthcare industries, his core areas of expertise include contract management services for sleep and respiratory services, along with acute care hospital operations and developing improved patient solutions in the aged care industry. Mr. Mathias' appointment provides the Board with additional depth and expertise as it moves from clinical development towards regulatory approval and commercialisation for its proprietary MEB-001 algorithm with the effective screening of a current Major Depressive Episode (cMDE) in the US market.
공시 • May 02TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 70,970,745 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 29,029,255 Price\Range: AUD 0.025 Discount Per Security: AUD 0.0015 Transaction Features: Subsequent Direct Listing
공시 • Oct 06Medibio Limited, Annual General Meeting, Nov 29, 2023Medibio Limited, Annual General Meeting, Nov 29, 2023, at 09:00 W. Australia Standard Time. Location: COMO The Treasury, Executive Boardroom, 1 Cathedral Avenue, Perth WA 6000 Australia
공시 • Feb 18Medibio Limited Appoints Christopher Ntoumenopoulos as DirectorMedibio Limited announced the appointment of Christopher Ntoumenopoulos as Director of the company. The date of appointment is 15 February 2023.